Stroke Devices: Hope Amid Headwinds
Executive Summary
Despite market headwinds, the endovascular treatment of acute ischemic stroke remains a growing and highly under-penetrated market opportunity valued at more than $1 billion worldwide. Although advances in neurothrombectomy devices, access catheters, imaging, and neuroprotective therapies have the potential to help expand the treatable population, positive Level I clinical evidence is needed to drive adoption and market growth.
You may also be interested in...
Fewer Than Half Of Children On Medicaid Receive Life-Saving Sickle-Cell Screenings, CDC Says
A CDC study found that fewer than half of children with sickle cell disease were getting screened for strokes, and fewer than 40% of children were taking recommended medications.
Endovascular Devices Headline International Stroke Conference
The American Heart Association-sponsored conference in Nashville featured late-breaking presentations of data from several major neurointerventional device trials as well as meta-analysis and pooled results confirming the benefits of endovascular intervention in several difficult-to-treat populations of stroke patients.
Neurointerventional Device Update: The Burgeoning Stroke Toolbox
The treatment of acute ischemic stroke and brain aneurysms is rapidly evolving. New transcatheter devices and adjuvant imaging promising to improve outcomes and reduce the burden of neurovascular disease. However, to really spur this market, long-term, large-scale clinical trials are needed.